Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 3/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2665097 | 1.00 | CYP2D6 (0.48) | CYP2D6MAOBMAOACYP1A1CYP1B1 | |
| SCHEMBL7062924 | 0.93 | MAPT (0.49) | CYP2D6MAOBCYP1A1CYP1B1NPC1 | |
| SCHEMBL2647392 | 0.81 | CYP2D6 (0.63) | CYP2D6MAOBMAOACYP1A1CYP1B1 | |
| SCHEMBL2664943 | 0.80 | NPC1 (0.54) | MAOBMAOACYP1A1CYP1B1STAT3 | |
| SCHEMBL2648657 | 0.80 | NPC1 (0.54) | MAOBMAOACYP1A1CYP1B1STAT3 | |
| SCHEMBL3746448 | 0.77 | CYP1A1 (0.58) | MAOBMAOACYP1A1CYP1B1STAT3 | |
| SCHEMBL2646520 | 0.76 | ABCG2 (0.63) | CYP2D6MAOBNPC1RAB9AMAPT | |
| SCHEMBL25216348 | 0.76 | F3 (0.68) | CYP2D6MAOBMAOACYP1A1CYP1B1 | |
| SCHEMBL25237641 | 0.76 | F3 (0.68) | CYP2D6MAOBMAOACYP1A1CYP1B1 | |
| SCHEMBL25212966 | 0.76 | F3 (0.68) | CYP2D6MAOBMAOACYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | CYP2D6 2704/4885MAOB 3317/4885MAOA 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.